Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Do you recommend consolidation immunotherapy after SBRT or surgery and chemo for T1-T2N0 SCLC?
Related Questions
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?
Would you offer empiric lung SBRT for two growing FDG-avid lung lesions in a patient with severe COPD on oxygen?
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Would you give lung SBRT to a patient with bullous pemphigoid on the chest and torso?
What is your approach to adjuvant RT or chemoRT in LS-SCLC s/p lobectomy with N1 disease?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Is there a concern for using FFF beams in single isocenter multi target lung SBRT?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
